Patient-derived xenograft (PDX) models provide a predictive preclinical model for the evaluation of an agent’s efficacy prior to entering the clinic. The CrownBio collection of PDX Pancreatic cancer contains over 100 models, including models of both North American and Asian descent. CrownBio offers a large collection of over 100 well characterized Pancreatic cancer PDX models.
Our Pancreatic cancer Patient-derived xenograft models offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, Patient derived xenograft reflects the heterogeneity and diversity of the human patient population. A Pancreatic cancer (PDX) model will give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s Pancreatic cancer PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
Learn More at: https://models.crownbio.com/model/pdx/pancreatic-cancer/